Oral ginseng formulae for stable chronic obstructive pulmonary disease: a systematic review.

Ginseng alone or combined with other herbs has been increasingly used for chronic obstructive pulmonary disease (COPD). This review aims to evaluate the effectiveness and safety of oral Ginseng formulae for stable COPD. Four English databases and three Chinese databases were searched to identify randomized controlled trials. Methodological quality was assessed by Cochrane risk of bias and Jadad's scale. Data were analyzed using Review Manager 5.0. Twelve studies overall of low quality, involving 1560 participants were included. Results of three studies showed a mean difference (MD) of 0.30 (95%CI 0.02 to 0.58) for forced expiratory volume in 1 s (FEV(1)) improvement of Ginseng formulae versus placebo control. Findings of three studies revealed an MD of 9.43 (95%CI 3.64 to 15.21) of FEV(1) % predicted between Ginseng formulae and placebo control. Quality of life (Qol) measured by St. George's Respiratory Questionnaire was improved (MD -10.32, 95%CI -14.99 to -5.65) with Ginseng formulae plus pharmacotherapy versus pharmacotherapy alone in one study. There were no severe adverse events reported. Ginseng formulae for stable COPD patients show promising evidence of lung functions and Qol improvement. However, the degree of benefit is uncertain due to potential risk of bias of the included studies.

[1]  T. Perez,et al.  Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[2]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[3]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[4]  C. Xue,et al.  A population survey on the use of 24 common medicinal herbs in Australia , 2008, Pharmacoepidemiology and drug safety.

[5]  Buist As.  Standardization of spirometry. , 1987 .

[6]  E. Yoo,et al.  In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists. , 2001, Planta medica.

[7]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[8]  Liam Ck.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .

[9]  S. Saydah,et al.  Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. , 2006, Journal of alternative and complementary medicine.

[10]  Hong Wang,et al.  Clinical observation of Qi deficiency syndrome in 72 patients with chronic obstructive pulmonary disease treated with Yiqi Mianyi Granule , 1996, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[11]  J. Cho,et al.  In vitro inhibitory effect of protopanaxadiol Ginsenosides on tumor necrosis factor (TNF)-α production and its modulation by known TNF-α antagonists , 2001 .

[12]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[13]  J. Hyun,et al.  Ginseng saponin metabolite suppresses phorbol ester–induced matrix metalloproteinase‐9 expression through inhibition of activator protein‐1 and mitogen‐activated protein kinase signaling pathways in human astroglioma cells , 2006, International journal of cancer.

[14]  Gao Ling-yun,et al.  Effect of Yufeining on induced sputum interleukin-8 in patients with chronic obstructive pulmonary disease at the stable phase , 2005 .

[15]  R. Efrat,et al.  Ginseng improves pulmonary functions and exercise capacity in patients with COPD. , 2002, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[16]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[17]  P. Frith,et al.  The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003 , 2003, The Medical journal of Australia.

[18]  E. Ernst,et al.  Panax ginseng: a systematic review of adverse effects and drug interactions. , 2010, Drug safety.

[19]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[20]  심범상.  Report on the Development of WHO International Standard Terminologies and International Classification of Traditional Medicine/Western Pacific Regional Office , 2007 .

[21]  Shengming Liu,et al.  Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. , 2007, American journal of respiratory and critical care medicine.

[22]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[23]  E. McCarthy,et al.  Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. , 2008, Journal of alternative and complementary medicine.

[24]  N. D. Kim,et al.  Glucocorticoid receptor-induced down-regulation of MMP-9 by ginseng components, PD and PT contributes to inhibition of the invasive capacity of HT1080 human fibrosarcoma cells. , 1999, Molecules and cells.

[25]  D. Mannino,et al.  International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.

[26]  S. K. Lee,et al.  Inhibition of oxidative DNA damage, 8-OHdG, and carbonyl contents in smokers treated with antioxidants (vitamin E, vitamin C, beta-carotene and red ginseng). , 1998, Cancer letters.

[27]  E. Ernst,et al.  Herbal medicines for the treatment of COPD: a systematic review , 2006, European Respiratory Journal.